| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 7,291,709
- Publication Date: November 06, 2007
- Appl. No: 10/650507
- Application Filed: August 27, 2003
- Assignees: Serono Genetics Institute S.A. (Evry, FR), Institut National de la Sante de la Recherche Medicale (INSERM) (Paris, FR)
- Claim: 1. A purified or recombinant Lipolysis Stimulated Receptor, wherein said receptor comprises a polypeptide having at least 90% homology to the polypeptide of SEQ ID NO: 8 and wherein said polypeptide has at least one biological activity selected from the group consisting of fatty acid binding, clathrin binding leptin binding, and lipoprotein binding.
- Claim: 2. A purified or recombinant Lipolysis Stimulated Receptor that a) comprises the amino acid sequence of SEQ ID NO:8; or b) consists of the amino acid sequence of SEQ ID NO:8.
- Claim: 3. The purified or recombinant receptor of claim 2 , wherein said receptor comprises the amino acid sequence of SEQ ID NO:8.
- Claim: 4. The polypeptide of claim 3 , wherein said polypeptide combines with one or more heterologous polypeptides to form an LSR receptor complex, and wherein said complex comprises an α subunit or an α′ subunit, and at least one β subunit.
- Claim: 5. The polypeptide of claim 4 , wherein said complex comprises three β subunits.
- Claim: 6. The polypeptide of claim 4 , wherein said polypeptide is from a human, and wherein said polypeptide has a molecular weight of 64 kD.
- Claim: 7. The polypeptide of claim 4 , wherein said polypeptide is expressed in hepatic cells.
- Claim: 8. The polypeptide of claim 4 , wherein said complex has a biological activity selected from the group consisting of lipoprotein binding, lipoprotein internalization, and lipoprotein degradation.
- Claim: 9. The polypeptide of claim 4 , wherein said complex has a biological activity that is selected from the group consisting of leptin binding, leptin internalization, and leptin degradation.
- Claim: 10. A composition comprising the polypeptide of claim 3 .
- Claim: 11. The composition of claim 10 , further comprising a physiologically acceptable carrier.
- Claim: 12. The purified or recombinant receptor of claim 2 , wherein said receptor consists of the amino acid sequence of SEQ ID NO:8.
- Claim: 13. An isolated or recombinant biologically active polypeptide fragment of SEQ ID NO: 8, said fragment comprising an amino acid sequence selected from the group consisting of: a) an amino acid sequence spanning amino acids 76 to 94 of SEQ ID NO:8; b) an amino acid sequence spanning amino acids 76 to 160 of SEQ ID NO:8; c) an amino acid sequence spanning amino acids 76 to 237 of SEQ ID NO:8; d) an amino acid sequence spanning amino acids 157 to 249 of SEQ ID NO:8; e) an amino acid sequence spanning amino acids 236 to 530 of SEQ ID NO:8; f) an amino acid sequence spanning amino acids 236 to 613 of SEQ ID NO: 8; and g) an amino acid sequence spanning amino acids 76 to 613 of SEQ ID NO:8.
- Claim: 14. The polypeptide fragment of claim 13 , wherein said polypeptide combines with one or more heterologous polypeptides to form an LSR receptor complex, and wherein said complex comprises an α subunit or an α′ subunit, and at least one β subunit.
- Claim: 15. The polypeptide fragment of claim 14 , wherein said complex comprises three β subunits.
- Claim: 16. The polypeptide fragment of claim 14 , wherein said polypeptide is from a human, and wherein said polypeptide has a molecular weight of 64 kD.
- Claim: 17. The polypeptide fragment of claim 14 , wherein said polypeptide is expressed in hepatic cells.
- Claim: 18. The polypeptide fragment of claim 14 , wherein said complex has a biological activity selected from the group consisting of lipoprotein binding, lipoprotein internalization, and lipoprotein degradation.
- Claim: 19. The polypeptide fragment of claim 14 , wherein said complex has a biological activity that is selected from the group consisting of leptin binding, leptin internalization, and leptin degradation.
- Claim: 20. The polypeptide fragment of claim 13 , wherein said polypeptide is recombinant.
- Claim: 21. A composition comprising the polypeptide of claim 13 .
- Claim: 22. The composition of claim 21 , further comprising a physiologically acceptable carrier.
- Claim: 23. The isolated or recombinant biologically active polypeptide fragment of claim 13 , said fragment comprising an amino acid sequence selected from the group consisting of: a) an amino acid sequence spanning amino acids 76 to 94 of SEQ ID NO:8 that contains a fatty acid binding site; b) an amino acid sequence spanning amino acids 76 to 160 of SEQ ID NO:8 that contains a fatty acid binding site and a clathrin binding site; c) an amino acid sequence spanning amino acids 76 to 237 of SEQ ID NO:8 that contains a fatty acid binding site, a clathrin binding site and contains a transport signal; d) an amino acid sequence spanning amino acids 157 to 249 of SEQ ID NO:8 that contains a clathrin binding site and contains a transport signal; e) an amino acid sequence spanning amino acids 236 to 530 of SEQ ID NO:8 and that contains a transport signal, a leptin binding site and a RSRS motif; f) an amino acid sequence spanning amino acids 236 to 613 of SEQ ID NO: 8 and that contains a transport signal, a leptin binding site, a RSRS motif, and a lipoprotein binding site; and g) an amino acid sequence spanning amino acids 76 to 613 of SEQ ID NO:8 and that contains a fatty acid binding site, a clathrin binding site, contains a transport signal, contains a leptin binding site, contains an RSRS motif, and has a lipoprotein binding site.
- Current U.S. Class: 530/350
- Patent References Cited: 5194596 March 1993 Tischer et al. ; 5270170 December 1993 Schatz et al. ; 5350836 September 1994 Kopchick et al. ; 5635373 June 1997 Wozney et al. ; 6126939 October 2000 Eisenbach-Schwartz et al. ; 6344441 February 2002 Bihain et al. ; 6579852 June 2003 Fruebis et al. ; 2002/0165154 November 2002 Bihain et al. ; 2003/0100500 May 2003 Fruebis et al. ; 2004/0067881 April 2004 Fruebis et al. ; WO 96/30400 October 1996 ; WO 96/34981 November 1996 ; WO 96/39429 December 1996 ; WO 97/27286 July 1997 ; WO 98/01257 January 1998 ; WO 98/20165 May 1998
- Other References: Steingrimsson et al., Database UniProt—7.2, Accession No. Q61148, Nov. 1, 1996 (sequence alignment). cited by examiner ; Vukicevic et al., 1996, PNAS USA 93:9021-9026. cited by examiner ; Alexeev and Yoon “Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide,” Nature Biotech. (1998), vol. 16, pp. 1343-1346. cited by other ; Austin, et al. “Hypertriglyceridemia as a Cardiovascular Risk Factor,” Am. J. Cardiol. (1998), vol. 81, pp. 7B-12B. cited by other ; Baldo, et al. “The Adipsin-Acylation Stimulating Protein System and Regulation of Intracellular Triglyceride Synthesis,” J. Clin. Invest. (1993), vol. 92, pp. 1543-1547. cited by other ; Bartles, J.R., et al. “Biogenesis of the Rate Hepatocyte Plasma Membrane,” Methods Enzymol. (1990), vol. 191, pp. 825-841. cited by other ; Bihain, et al. “Characterization and purification of the lipolysis-stimulated receptor,” INSERM U391, Universite de Rennes. cited by other ; Bihain, et al. “Free Fatty Acids Activate a High Affinity Saturable Pathway for Degrdation of Low-Density Lipoproteins in Fibroblasts from a Subject Homozygous for Familial Hypercholesterolemia,” Biochemistry (1992), vol. 31, No. 19, pp. 4628-4636. cited by other ; Brendel, V. et al. “Methods and algorithms for statistical analysis of protein sequences,” Proc. Natl. Acad. Sci. USA (1992), vol. 89, pp. 2002-2006. cited by other ; Chen, W.J. et al. “NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor,” J. Biol. Chem. (1990), vol. 265, pp. 3116-3123. cited by other ; Cole-Strauss et al. “Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA Oligonucleotide,” Science (1996), vol. 273, pp. 1386-1389. cited by other ; Davis, C.G. et al. “The J.D. Mutation in Familial Hypercholesterolemia: Amino Acid Substitution in Cytoplasmic Domain Impedes Internalization of LDL Receptors,” Cell (1986), vol. 45, pp. 15-24. cited by other ; Dietrich, J. et al. “CD3y Contains a Phosphoserine-Dependent Di-Leucine Motif Involved in Down-Regulation of the T Cell Receptor,” EMBO Journal (1994), vol. 13, pp. 2156-2166. cited by other ; Everhart, J.E. “Weight Change and Obesity After Liver Transplantation: Incidence and Risk Factors,” Liver Transpl. Surg. (1998), vol. 4, pp. 285-296. cited by other ; Freeman, Jr., W.E. “Hypertriglyceridemia and Atherosclerosis,” Annals of Internal Med. (1998), vol. 128, No. 1, pp. 73-74. cited by other ; Ghebrehiwet, et al. “Isolation, cDNA Cloning, and Overexpression of a 33-kD Cell Surface Glycoprotein that Binds to the Globular “Heads” of C1q,” J. Exp. Med. (1994), vol. 179, No. 6, pp. 1809-1821. cited by other ; Goldstein, J.L., et al. “Familial Hypercholesterolemia,” in The Metabolic and Molecular Bases of Inherited Disease (vol. II, 7th ed., Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, B. editors, 1995), pp. 1981-2030; McGraw-Hill; New York, New York, USA. cited by other ; Goldstein, et al. “Hyperlipidemia in Coronary Heart Disease,” J. Clin. Invest. (1973), vol. 52, pp. 1533-1543. cited by other ; Gura, et al. “Obesity Sheds Its Secrets,” Science (1997), vol. 275, pp. 751-753. cited by other ; Hayward, et al. “The cDNA Sequence of Human Endothelial Cell Multimerin,” J. Biol. Chem. (1995), vol. 270, pp. 18246-18251. cited by other ; Henrion, et al. “Structure, Sequence and Chromosomal Location of the Gene for USF2 Transcription Factors in Mouse,” Genomics (1995), vol. 25, pp. 36-43. cited by other ; Herz, J., et al. “Surface Location and High Affinity for Calcium of a 500-kd liver Membrane Protein Closely Related to the LDL-receptor Suggest a Physiological Role as Lipoprotein Receptor,” European Molecular Biology Laboratory (1988), vol. 7, pp. 4119-4127. cited by other ; Honore, B., et al. “Cloning and Expression of a cDNA Covering the Complete Coding Region of the P32 subunit of Human pre-mRNA Splicing Factor SF2,” Gene (1993), vol. 134, pp. 283-287. cited by other ; Hu, E., et al. “AdipoQ is a Novel Adipose-specific Gene Dysregulated in Obesity,” J. Biol. Chem. (1996), vol. 271, No. 18, pp. 10697-10703. cited by other ; Huettinger, M., et al. “Charecteristics of Chlylomicron Remnant Uptake into Rat Liver,” Clin. Biochem. (1988), vol. 21, pp. 87-92. cited by other ; Karpe, F., et al. “Clearance of Lipoprotein Remnant Particles in Adipose Tissue and Muscle in Humans,” J. Lipid, Res. (1997), vol. 38, pp. 2335-2343. cited by other ; Karpe, F., et al. “Magnitude of Alimentary Lipemia is Related to Intima-media Thickness of the Common Carotid Artery in Middle-aged Men,” Elsevier Science Ireland (1998), vol. 141, pp. 307-314. cited by other ; Krainer, A.R., et al. “Functional Expression of Cloned Human Splicing Factor SF2: Homology to RNA-Binding Proteins, U1 70K, and Drosophila Splicing Regulators,” Cell (1991), vol. 66, pp. 383-394. cited by other ; Lee, M. G-S., et al. “Charecterization of a cDNA Encoding a Cysteine-Rich Cell Surface Protein Located in the Flagellar Pocket of the Protozoan Trypanosoma brucei,” Molec. Cell. Biol. (1990), vol. 10 pp. 4506-4517. cited by other ; Letourneur, F., et al. “A Novel Di-Leucine Motif and a Tyrosine-Based Motif Independently Mediate Lysosomal Targeting and Endocytosis of CD3 Chains,” Cell (1992), vol. 69, pp. 1143-1157. cited by other ; Lewis, G.F., et al. “Postprandial Lipoprotein Metabolism in Normal and Obese Subjects: Comparison after the Vitamin A Fat-Loading Test,” J. of Clinic. Endo. (1990), vol. 71, pp. 1041-1050. cited by other ; Lin, et al. “Archaic Structure of the Gene Encoding Transcription Factor USF,” Journal of Biological Chemistry (1994), vol. 269, No. 19, pp. 23894-28903. cited by other ; Liu, Q., et al. “Design of Polydactyl Zinc-finger Proteins for Unique Addressing within Complex Genomes,” Proc. Natl. Acad. Sci. USA (1997), vol. 94, pp. 5525-5530. cited by other ; Maeda, et al. “cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1 (Adipose Most Abundant Gene Transcript 1),” Biochem. And Biophys. Research Comm. (1996), vol. 221, pp. 286-289. cited by other ; Mahley, R.W., et al. “Type III Hyperlipoproteinemia (Dysbetalipoproteinemia): The Role of Apolipoprotein E in Normal and Abnormal Lipoprotein Metabolism,” The Molecular Basis of Inherited Disease (1995), pp. 1953-1980; Scriver CR, Beaudet, A.L., Sly, W.S., Valle, D., editors; McGraw-Hill; New York. cited by other ; Mann, et al. “Mechanism of Activation and Functional Significance of the Lipolysis-Stimulated Receptor. Evidence for Role as Chylomiscron Remnant Receptor,” Biochemistry (1995), vol. 34, No. 33, pp. 10421-10431. cited by other ; Massie, et al. “Inducible Overexpression of a Toxic Protein by an Andenovirus Vector with a Tetracycline-Regulatable Expression Cassette,” Journal of Virology (1998), vol. 72, pp. 2289-2296. cited by other ; Montague, et al. “Congenial Leptin Deficiency is Associated with Severe Early-onset Obesity in Humans,” Nature (1997), vol. 387, pp. 903-908. cited by other ; Parra-Lopez, C.A., et al. “Presentation on Class II MHC Molecules of Endogenous Lysozyme Targeted to the Endocytic Pathway,” J. Immunol. (1997), vol. 158, pp. 2670-2679. cited by other ; Pengue, G., et al. “Repression of Transcriptional Activity at a Distance by the Evolutionary Conserved KRAB Domain Present in a Subfamily of Zinc Finger Proteins,” Nucleic Acids Research (1994), vol. 22, No. 15, pp. 2908-2914. cited by other ; Rajput-Williams,J., et al. “Variation of Apolipoprotein-B Gene is Associated with Obesity, High Blood Cholesterol Levels, and Increased Risk of Coronary Heart Disease,” The Lancet (1988), pp. 1442-1446. cited by other ; Rutherford, S., et al. “Association of a Low Density Lipoprotein Receptor Micro-satellite Variant with Obesity,” Intl. J. of Obesity (1997), vol. 21, pp. 1032-1037. cited by other ; Schaffler, et al. “Identification and Characterization of the Human Adipocyte apM-1 Promoter,” Biochem. and Biophys. Res. Comm. (1998), vol. 1399, pp. 187-189. cited by other ; Scherer, et al. “A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes,” J. Biol. Chem. (1995), vol. 270, pp. 26746-26749. cited by other ; Sellar, et al. “Characterization and Organization of the Genes Encoding the A-, B-, and C-chains of human complement subcomponent C1q,” Biochemical Journal (1991), vol. 274, pp. 481-490. cited by other ; Shimabukuro, M., et al. “Direct Antidiabetic Effect of Leptin Through Triglyceride Depletion of Tissues,” Proc. Natl. Acad. Sci. USA (1997), vol. 94, pp. 4637-4641. cited by other ; Shimano, H., et al. “Overproduction of Cholesterol and Fatty Acids Causes Massive-Liver Enlargement in Transgenic Mice Expression Truncated SREBP-1a,” J. Clin. Invest. (1996), vol. 98, pp. 1575-1584. cited by other ; Shin, J., et al. “Phosphorylation-dependent Down-modulation of CD4 Requires a Specific Structure within the Cytoplasmic Domain of CD4,” J. of Biol. Chem. (1991), vol. 266, pp. 10658-10665. cited by other ; Simos, G., et al. “The lamin B Receptor-associated Protein p34 Shares Sequences Homology and Antigenetic Determinants with the Splicing Factor 2-associated with Protein p32,” FEBS Letters (1994), vol. 346, pp. 225-228. cited by other ; Steingrimsson, et al. “Murine Chromosomal Location of Five bHLH-Zip Transcription Factor Genes,” Genomics (1995), vol. 28, pp. 179-183. cited by other ; Troussard, et al. “Inhibitory Effect on the Lipolysis-stimulated Receptor of the 39-kDa Receptor-associated Protein,” Journal of Biological Chemistry (1995), vol. 270, No. 29, pp. 17068-17071. cited by other ; Urade, Y., et al. “Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement C1q B chain,” Proc. Natl. Sci. USA (1991), vol. 88, pp. 1069-1073. cited by other ; Van Den Berg, R.H., et al. “Intracellular Localization of the Human Receptor for the Globular Domains of C1q,” American Association of Immunologist (1997), vol. 158, pp. 3909-3916. cited by other ; Verhey, K.J., et al. “A Leu-Leu Sequence is Essential for COOH-terminal Targeting Signal of GLUT4 Glucose Transporter in Fibroblasts,” J. Biol. Chem. (1994), vol. 269, pp. 2353-2356. cited by other ; Wang, et al. “Upstream Stimulatory Factor Binding to the E-box at -65 is required for Insulin Regulation of the Fatty Acid Synthase Promoter,” J. Biol. Chem. (1997), vol. 272, pp. 26367-26374. cited by other ; Yen, et al. “Identification of a Lipolysis-Stimulated Receptor That is Distinct from the LDL Receptor and the LDL Receptor Related Protein,” Biochemistry (1994), vol. 33, No. 5, pp. 1172-1180. cited by other ; Zhang, M., et al. “Tumor Necrosis Factor,” in The Cytokine Handbook (3rd ed., 1998), pp. 517-548. cited by other ; Zhong, G. et al. “Related Leucine-based Cytoplasmic Targeting Signals in Invariant Chain and Major Histocompatibility Complex Class II Molecules Control Endocytic Presentation of Distinct Determinants in a Single Protein,” J. Exp. Med. (1997), vol. 185, pp. 429-438. cited by other ; DATABASE EMBL, Entry MM49507, Accession No. U49507, May 20, 1996. cited by other ; DATABASE SPTREMBL—17, Accession No. Q61148, Nov. 1, 1996. cited by other ; DATABASE EMBL, Q61127, Accession No. Q61148, Nov. 1, 1996. cited by other ; DATABASE EMBL, Entry HSUSF2, Y07661, Jan. 24, 1997. cited by other ; DATABASE EMBL, Entry HSAD684, AD000684, Mar. 26, 1997. cited by other ; DATABASE EMBL, Entry HSAC2128, AC002128, May 28, 1997. cited by other ; DATABASE EMBL, Entry 000112, 0001127, Jul. 1, 1997. cited by other ; DATABASE EMBL, Entry 000426, 000426, Jul. 1, 1997. cited by other ; DATABASE SPTREMBL—17, Accession No. O00426, Jul. 1, 1997. cited by other ; DATABASE SPTREMBL—17, Accession No. O00112, Jul. 1, 1997. cited by other ; Mann, et al. Abstract: “ApoC111 Inhibits the Binding of Triglyceride-Rich Lipoproteins to the Lipolysis Stimulated Receptor,” Circulation (1996), vol. 94, No. 8, supp.I-698. cited by other ; U.S. Appl. No. 10/072,159, filed Feb. 5, 2002, Bihain et al. cited by other
- Primary Examiner: O'Hara, Eileen B.
- Attorney, Agent or Firm: Saliwanchik, Lloyd & Saliwanchik
|
